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Abstract: Stroke, as the leading cause of physical disability and cognitive impairment, has a very
significant impact on patients’ quality of life (QoL). The objective of this study is to know the
effect of citicoline treatment in Qol and cognitive performance in the long-term in patients with
a first ischemic stroke. This is an open-label, randomized, parallel study of citicoline vs. usual
treatment. All subjects were selected 6 weeks after suffering a first ischemic stroke and randomized
into parallel arms. Neuropsychological evaluation was performed at 1 month, 6 months, 1 year
and 2 years after stroke, and QoL was measured using the EuroQoL-5D questionnaire at 2 years.
163 patients were followed during 2 years. The mean age was 67.5 years-old, and 50.9% were women.
Age and absence of citicoline treatment were independent predictors of both utility and poor quality
of life. Patients with cognitive impairment had a poorer QoL at 2 years (0.55 vs. 0.66 in utility,
p = 0.015). Citicoline treatment improved significantly cognitive status during follow-up (p = 0.005).
In conclusion, treatment with long-term citicoline is associated with a better QoL and improves
cognitive status 2 years after a first ischemic stroke.
Keywords: quality of life; ischemic stroke; citicoline; cognitive impairment
1. Introduction
Although age-standardized rates of stroke mortality have decreased worldwide in the past two
decades, the absolute number of people who have a stroke every year, stroke survivors, related deaths,
and the overall global burden of stroke (DALYs lost) are great and increasing [1]. We must remain
mindful that substantial post-stroke disability is considered a worse outcome than death for many
people. The presence of stroke represents a nearly 1.9 fold increase in cognitive decline [2]. Almost
half of stroke survivors have cognitive impairment [3]. Cognitive decline after stroke is even more
common than stroke recurrence [4]. Cognitive impairment causes loss on independence for activities
of daily living and may accelerate the need of institutionalization [5,6], and quality of life declines after
first ischemic stroke [7]. Thus, an increased focus on stroke survivors, in particular of their cognitive
and physical function, is needed. Quality of life (QoL) after stroke is of vital concern for survivors, so
understanding the factors that can influence on it is necessary to help stroke survivors.
Among various scales available for measuring QoL, one of the most commonly used is the
EuroQoL-5D, a scale that has demonstrated its value and reliability for measuring quality of life in
patients who have suffered a stroke [8,9].
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Our objective is to know the effect of citicoline treatment in Qol and cognitive performance in the
long-term in patients with a first ischemic stroke.
2. Results
A total of 163 patients who had suffered a first ischaemic stroke were assessed after 2 years.
The mean age was 67.5 ˘ 10.7 years and 83 (50.9%) were women. Among the risk factors, 60.1% of
patients had hypertension, 40.5% dyslipidaemia and 30.9% diabetes mellitus; 29.4% were smokers,
and 12.3% had atrial fibrillation. Stroke severity, measured using baseline NIHSS, was 13 (10–16).
86 patients (52.8%) were being treated with citicoline and 77 (47.2%) were not. Baseline characteristics
of patients that received and did not received citicoline are shown in Table 1. During the follow-up
period, 13 patients (8%) had stroke recurrence, 7 (8.1%) treated with citicoline and 6 (7.8%) not
treated (p = 0.935). Quality of life of these patients at 2-year follow-up according to the EuroQoL-5D
questionnaire is shown in Figure 1, where the involvement of each dimension on the scale is represented.
The mean overall Utility index was 0.63 ˘ 0.28, with 37 (22.7%) patients being classified within the
group with poor or very poor quality of life (utility < 0.5). The median VAS scale score was 70 (50–85)
with a range from 0 to 100.
Table 1. Baseline characteristics in patients who received and did not received citicoline.
Parameters
Citicoline p
Yes (n = 86) No (n = 77)
Sex (female) 54.7% 46.8% 0.314
Age 68.5 ˘ 9.8 66.4 ˘ 11.4 0.200
Years of education 5.8 ˘ 3.7 5.1 ˘ 3.3 0.173
Smoking 24.4% 35.1% 0.137
Alcohol 17.4% 24.7% 0.256
Dyslipidaemia 34.9% 46.8% 0.123
Diabetes mellitus 38.4% 24.7% 0.061
Hypertension 59.3% 61%) 0.821
Atrial Fib. 12.8% 11.7% 0.830
Coronary heart disease 4.7% 10.4% 0.161
AMI 11.6% 14.3% 0.613
PAD 4.7% 5.2% 1.000
Baseline NIHSS 13 (10–16) 14 (10–16.5) 0.518
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The comparison of utility with demographic variables, risk factors and severity (Table 2) showed
that women who had suffered a stroke had a worse quality of life (0.58 vs. 0.67; p = 0.030). Similarly,
older patients (p = 0.046), with a higher initial stroke severity (p = 0.016) and those with PAD (p = 0.047)
were also significantly correlated with a worse utility. Patients with previous hypertension presented
a tendency to have a worse quality of life (0.59 vs. 0.67; p = 0.078), although this difference was
not statistically significant. The analysis between patients who took citicoline and those who did
not, showed that the patients being treated with this drug had significantly better QoL than the rest
(0.67 ˘ 0.26 vs. 0.58 ˘ 0.30; p = 0.041). A multivariate analysis using a linear regression model showed
age (β =´0.005 [95%CI: ´0.009, ´0.001]; p = 0.024) and treatment with citicoline (β = 0.112 [95%CI:
0.027, 0.198]; p = 0.010) as independent predictors of utility. Thus, for each 10-year increase in patient’s
age, utility decreased by a mean of 0.05 points; therefore quality of life worsens with age. Furthermore,
irrespective of age, patients who took citicoline improved their quality of life according to this index
by a mean of 0.112 points.
Table 2. Utility according to demographic variables, risk factors, and severity.
Parameters Utility p
Sex
Male 0.67 ˘ 0.27
0.030Female 0.58 ˘ 0.29
Age R: ´0.156 0.046
Years of education R: 0.081 0.306
Smoking No 0.62 ˘ 0.27 0.670Yes 0.64 ˘ 0.31
Alcohol
No 0.64 ˘ 0.29
0.306Yes 0.58 ˘ 0.27
Dyslipidaemia No 0.63 ˘ 0.26 0.763Yes 0.62 ˘ 0.31
Diabetes mellitus
No 0.64 ˘ 0.28
0.316Yes 0.59 ˘ 0.29
Hypertension No 0.67 ˘ 0.26 0.078Yes 0.59 ˘ 0.29
Atrial Fib.
No 0.64 ˘ 0.27
0.199Yes 0.53 ˘ 0.35
Coronaryheart disease No 0.62 ˘ 0.29 0.521Yes 0.68 ˘ 0.24
AMI
No 0.62 ˘ 0.28
0.465Yes 0.67 ˘ 0.30
PAD
No 0.64 ˘ 0.28
0.047Yes 0.43 ˘ 0.30
Baseline NIHSS R: ´0.188 0.016
R: correlation coefficient.
The variables associated with poor or very poor quality of life are shown in Table 3. Only old age
was significantly associated with a poor quality of life (70.7 vs. 66.6; p = 0.039). Moreover, although
not achieving statistically significant differences, there was a trend for females (p = 0.054), patients
with hypertension (p = 0.069), and those with PAD (p = 0.079) of having worse quality of life. When
treatment with citicoline was analysed, we observed that 28.6% of patients not receiving this drug had
a poor or very poor quality of life compared with 17.4% of those under treatment, these differences
did not achieve statistical significance (p = 0.090). After performing a logistic regression analysis, we
observed that age (OR 1.048 [95%CI: 1.010, 1.087]; p = 0.012) and the absence of citicoline treatment
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(OR 2.321 [95%CI: 1.057, 5.100]; p = 0.036) were independent predictors of poor or very poor quality of
life. After adjusting for age, treatment without citicoline was associated with a worse quality of life.
As seen in Figure 2, treatment with citicoline is associated with a better quality of life, both in older
age groups as well as in younger patients.
Table 3. Variables associated with poor or very poor quality of life.
Parameters
Quality of Life p
Good/Acceptable Poor/Very Poor
Sex (female) 46.8% 64.9% 0.054
Age 66.6 ˘ 10.2 70.7 ˘ 12.1 0.039
Years of education 5.7 ˘ 3.6 4.8 ˘ 3.2 0.152
Smoking 29.4% 29.7% 0.966
Alcohol 19.8% 24.3% 0.555
Dyslipidaemia 40.5% 40.5% 0.994
Diabetes mellitus 31.0% 35.1% 0.631
Hypertension 56.3% 73.0% 0.069
Atrial Fib. 10.3% 18.9% 0.161
Coronary heart disease 7.9% 5.4% 0.604
AMI 13.5% 10.8% 0.669
PAD 3.2% 10.8% 0.079
Baseline NIHSS 13 (10–16) 14 (11–17) 0.301
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60–64, 3rd:65–70, 4th:70–75, 5th: >75. 
In the VAS assessment, no significant differences were observed, but some variables as age (p = 
0.073), sex (p = 0.051) and PAD (p = 0.074) tended to be associated in the same way as they were with 
the utility. Patients treated with citicoline had also better scores on this scale (72.5 (50–90) vs. 70 
(40–80), p = 0.063), although differences did not achieve statistical significance. 
Patients treated with citicoline had less cognitive impairment at 2 year follow-up (27.9% vs. 
39%) without achieving statistically significant differences. However, citicoline group showed a 
significant improvement during follow-up (p = 0.005). (Figure 3). Untreated group did not show 
significant changes. 
Figure 2. Citicoline compared with quality of life for different age groups. Patients not treated with
citicoline were more likely to have a poor quality of life in all age subgroups. Quintiles: 1st: <60, 2nd:
60–64, 3rd:65–70, 4th:70–75, 5th: >75.
In the VAS assessment, no significant differences were observed, but some variables as age
(p = 0.073), sex (p = 0.051) and PAD (p = 0.074) tended to be associated in the same way as they were
with the utility. Patients treated with citicoline had also better scores on this scale (72.5 (50–90) vs.
70 (40–80), p = 0.063), although differences did not achieve statistical significance.
Patients treated with citicoline had less cognitive impairment at 2 year follow-up (27.9% vs. 39%)
without achieving statistically significant differences. However, citicoline group showed a significant
improvement during follow-up (p = 0.005). (Figure 3). Untreated group did not show significant changes.
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Figure 3. Global cognitive impairment during follow-up. Patients treated with citicoline show
a significant improvement in cognitive status during follow-up (* p = 0.005). After the first year,
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3. D scussion
As the leading cause of cognitive and physical disability, stroke has a very significant impact on
the quality of life of patients. The mean utility index in our study is 0.63 ˘ 0.28 and nearly one quarter
(22.7%) of the patients present a poor or very poor quality of life two years after a first ischaemic stroke.
Treatment with long-term citicoline improves cognitive status of stroke patients and is associated with
a better quality of life at 2 years.
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In previous studies where post-stroke QoL was measured [10–21], the utility measurement
varied between 0.47 and 0.88 (Table 4), which could be explained by the fact that the follow-up times
varied greatly between studies (from 3 months to 5 years) and that the type of stroke evaluated was
different from one study to another. These publications showed that patients with a better QoL, i.e.,
an utility of 0.88, are TIA patients with 3 months of follow-up [19], and conversely those patients
with a worse QoL, i.e., an utility of 0.47, are individuals with longer follow-up (2 years) including
ischemic and hemorrhagic strokes [10,15]. Although stroke type clearly had an influence, the follow-up
time did not seem to be as important in measuring quality of life, since according to the studies by
Luengo-Fernandez R., et al. [17] and López-Bastida J., et al. [15], the values of this index did not change
significantly between 6 months and 5 years of follow-up. Only an American study of first ischaemic
strokes [7] found a significant worsening in quality of life starting in the 3rd year, although the quality
of life index was measured in a different way (QLI) and there were no significant changes in those
patients with private health insurance.
The mean utility in our study was similar to two previous publications in which quality of life
in ischaemic strokes was evaluated [11,17]; 0.68 at the 4-year follow-up in the German study [11]
and 0.66 at the 2-year follow-up in the OXVASC trial from the UK [17]. The VAS scale values in the
trials evaluating stroke patients were similar to ours, with mean scores ranging from 51.6 to 67.3
(Table 4). Taking into account each of the dimensions of the EuroQoL-5D scale, we observed that usual
activities were the most disrupted in our study, affecting more than half of the patients. This was in
correlation with data of most of previous studies [13,18,20,22,23], having also patients more affected in
usual activities.
In the current study, women had worse quality of life at 2 years compared to men, which
agrees with the results of other studies [10–12,17,19,21]. If we focus on studies evaluating only
ischaemic stroke, men were significantly better in the OXVASC study [17] and it was even described as
an independent predictor of good quality life in a multivariate analysis; similar results were obtained
in the American study by Bushnell, C.D., et al. [21]. The German study [11] did not show statistically
significant differences although women had less quality of life. Furthermore, there is a more recent
study including only patients with ischaemic stroke (BASIC Project) [24] in which again a worse
prognosis was also found in the quality of life of women, being highly statistically significant after
an adjusted regression model. Similarly to most studies [7,10–12,17,19,25], older age was correlated
with a worse quality of life in our patients, remaining as an independent predictor in a multivariate
analysis, in agreement with most studies [7,10,17,19,22,25]. In our study, we also found a statistically
significant correlation with the initial stroke severity. This correlation was also established in all
the articles that evaluated this issue [7,10,13,17,19,21,23], and it was reported as an independent
predictor in most of them [7,10,17,19,21,23]. In this study, we found that treatment with citicoline was
an independent predictor of utility with a beta of 0.112 in the regression model. This means that the
mean utility of patients receiving citicoline is 0.112 higher than the rest of patients. Although this
difference is statistically significant, it does not seem to be a substantial change. However, it is difficult
to establish if this difference is clinically relevant or not, since there is not any known cutoff validated
in stroke patients.
Demonstrated efficacy of citicoline in improving cognitive functions after an ischaemic stroke [26]
may be responsible for this beneficial effect on post-stroke quality of life. Three studies in the literature
measured patient cognitive status using the mini mental examination [11,18,22] and in all of them
there were highly significant correlations with the utility, which would reinforce our hypothesis that
long-term treatment with citicoline at high doses would be associated with a better quality of life of
patients by improving patients’ neurocognitive function after a first ischemic stroke. Our study also
shows a progressive and significant improvement in cognitive status during follow-up when patients
are treated with long-term citicoline. This improvement is maintained even after the first year post
stroke, a period from which untreated patients begin to show a slight decrease of cognitive functions,
which could be an age-dependent effect. Moreover, the results of the present study also show that
patients with GCI have a poorer quality of life.
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Table 4. Literature review of recent quality of life studies using the EuroQoL-5D scale in stroke.
Study Year Country Follow-up n Stroke Type Utility orEquivalent VAS Sex Age NIHSS
Multivariate (Worse Quality of
Life) Other
Sturm, J.W., et al. [10] 2004 Australia 2 years 225 Ischaemic andhaemorrhagic
0.47 (95% CI
0.42–0.52) N.A.
Females
worse (sig.)
Old age
worse (sig.)
Worse with higher
NIHSS (sig.)
Age, sex, NIHSS, and socioecon.
status –
Haacke, C., et al. [11] 2006 Germany 4 years 54 Ischaemic 0.68 ˘ 0.33 56.5 Femalesworse (n.s.)
Old age
worse (sig.) N.A.
IB, anal continence, continence
and depression.
Worse with lower IB, higher
mRS, impairment (MMSE) and
depression.
Xie, J., et al. [12] 2006 USA >1 year 1040 Stroke 0.69 (SE 0.01) 61.6(SE 0.08)
Females
worse
Worse in old
age N.A. N.A. –
Pinto, E.B., et al. [13] 2011 Brazil 2 years 67 Stroke 0.52 ˘ 0.36 N.A. N.A.
No
correlation
with age (n.s.)
Worse with higher
NIHSS (sig.) N.A. –
Hansson, E.E., et al.
[14] 2012 Sweden 1 year 283 Stroke 0.5 ˘ 0.39 62.5 ˘ 21.8 N.A. N.A. N.A. N.A. –
López-Bastida, J.,
et al. [15] 2012
Canary
Islands,
Spain
1 year 94
Stroke
0.49 ˘ 0.42 56 ˘ 27
N.A. N.A. N.A. N.A.
Quality of life does not change
in 1–2–3 years.2 years 205 0.47 ˘ 0.44 51.6 ˘ 27
3 years 149 0.46 ˘ 0.45 55 ˘ 25
Hornslien, A.G., et al.
[16] (SCAST) 2012
Northern
Europe
6
months
870 Stroke: Candesartan
Placebo
0.74 (0.59–0.88)
0.78 (0.62–0.88)
66 ˘ 20
N.A. N.A. N.A. N.A.
MMSE: 28 (25–29); Does not
compare it with quality of life.882 67.3 ˘ 19
Luengo-Fernández,
R., et al. [17]
(OXVASC)
2013 UK
1 month
314 Ischaemic stroke
0.64 ˘ 0.33
N.A.
Females
worse (sig.)
Old age
worse (sig.)
Worse with higher
NIHSS (sig.)
Sex, Age, NIHSS, risk factors,
stroke type
Does not vary in 1–5 years.1 year 0.70 ˘ 0.27
2 years 0.66 ˘ 0.29
5 years 0.67 ˘ 0.31
Sprigg, N., et al. [18]
(ENOS) 2013
Countries
worldwide
3
months 2238
Ischaemic and
haemorrhagic N.A. 65.8 ˘ 22.4 N.A. N.A. N.A. N.A.
Worse with lower IB, higher
mRS, impairment (MMSE) and
depression.
Wang, Y.-L., et al. [19]
(CHANCE) 2014 China
3
months
5104 TIAs 0.88 ˘ 0.21 84 ˘ 15 Femalesworse (sig.)
Old age
worse (sig.)
Worse with higher
NIHSS (sig.)
Age, hypertension, DM, NIHSS,
and various treatments
Worse at higher mRS.
89 (80–85)
Golicki, D., et al. [20] 2014 Poland 4months 112 Stroke
0.691 ˘ 0.267 60.7 ˘ 22.4 N.A. N.A. N.A. N.A. Correlation with Barthel and
mRS60 (45.5–80)
Bushnell, C.D., et al.
[21] 2014 USA 1 year 1370
Ischaemic (including
TIAs) 0.83 (0.74–1) N.A.
Females
worse (sig.) N.A.
Worse with higher
NIHSS (sig.) NIHSS and sex
No changes in quality of life
during 1 year
Current study 2015 Spain 2 years 163 First ischaemic stroke
0.63 ˘ 0.28 64.4 ˘ 2570 (50–85) Femalesworse (sig.)
Old age
worse (sig.)
Worse with higher
NIHSS (sig.)
Age, treatment with citicoline –
0.70 (0.59–0.79)
N.A.: Not Available; n.s.: not significant; sig.: statistically significant; CI: Confidence interval; SE: Standard error; MMSE: Mini Mental State Examination.
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Apart from its neuroprotective effects, citicoline also possesses a substantial neuroregenerative
potential [27–34] that may explain better its beneficial effects in post-stroke cognitive impairment and
quality of life. Since experimental studies have shown that neurorepair mechanisms initiated after
cerebral ischemia remain active beyond twelve months [35], the use of drugs that enhance neurorepair
mechanisms as citicoline [27–34], would be indicated for periods of time longer than one year in order
to improve post-stroke sequelae and prevent cognitive decline associated with age, as shown by the
results of this study.
The study has some limitations. One of them is that the open-label design of the study could have
influenced our results; more specifically, some cognitive improvement in the citicoline group might be
attributable to patients’ expectation bias, so placebo-controlled studies are needed to better elucidate
the efficacy of citicoline in stroke patients. Another limitation of this study is that only the evaluation
of the quality of life at 2 years was contemplated. Having evaluations during early time points would
have probably allowed us having an idea of critical timing in improvement or drug administration.
However, considering the changes in cognitive performance and the relationship between cognitive
impairment and quality of life, it makes us think that quality of life of patients could have a similar
evolution in the follow-up.
In conclusion, stroke negatively impacts quality of life, especially in usual activities. Nearly one
quarter of ischaemic stroke survivors have a poor or very poor quality of life 2 years after the stroke.
Citicoline independently predicts a better quality of life at 2 years and improves cognitive status of
stroke patients during follow-up.
4. Materials and Methods
4.1. Patients
The patients participated in a study designed to measure the effect of long-term treatment with
citicoline (1g/day orally) on the cognitive functions of patients who had suffered a first ischaemic
stroke [26]. Appropriated secondary stroke prevention measures were used in all recruited patients.
When indicated, neurorehabilitation treatment was made according to the Stroke Unit protocol of
the Vall d’Hebron Hospital.Global cognitive status was defined as the mean of all standardized
(0–100) cognitive functions scores. It was considered as global cognitive impairment (GCI) an overall
score <40. More details on the neuropsychological assessment are described in the previous study
of Alvarez-Sabín J, et al. [26]. For the present study, we evaluated the patients who had completed
the 2-year follow-up. During all the follow-up time no patient received any drug that could modify
cognitive functions or alertness.
The study was approved by Vall d’Hebron Hospital IRB; informed consent was obtained in
all patients.
4.2. Quality of Life
Patient quality of life was measured using the EuroQoL-5D health questionnaire adapted for
use in Spain [36], in which five health dimensions were assessed: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression, each with three levels of severity (1: no problems, 2: some
problems or moderate problems, 3: serious problems). Based on this scale we were able to obtain
an overall index [37] (utility) ranging from 0 to 1, where 1 represented the patient without any health
problems or with the best possible health status and 0 the worst health status or death. Starting from
the best possible health status (utility = 1), each dimension affected could be penalised differently on
this scale [37]. This index was distributed similarly to the study of Christensen et al. [38], where utility
distribution revealed two groups of patients according to a cut-off point of 0.5. Thus, in line with
other studies [15,19], a utility score <0.5 was used to identify those patients with a poor or very poor
quality of life. These patients were characterised by being affected in some way in all dimensions or by
having a level 3 severity in at least one of them. The visual analogue scale (VAS) of the EuroQol-5D
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questionnaire was also assessed. This scale measures the patient’s subjective state using a thermometer
with scores ranging from 0 to 100, where 0 is the worst imaginable health status and 100 the best
imaginable health status.
4.3. Statistical Analysis
Statistical analysis was performed using the SPSS Statistics 17.0 software (SPSS Inc., Chicago,
IL, USA).
The comparisons made with the utility index were assessed using Student’s t-test for categorical
variables and Pearson’s correlation coefficient for continuous variables, except for the NIHSS scale
which was assessed with the Spearman’s correlation coefficient. A multiple linear regression analysis
was performed to obtain variables independently associated with a worse utility, including in the
model those variables with significance under 0.1 in the bivariate analysis.
The variables related with GCI and a worse quality of life (utility < 0.5) were assessed using
Pearson’s Chi-square test or, if necessary, Fisher’s exact test in categorical variables, and Student’s t-test
in numeric variables, except for NIHSS where the Mann-Whitney U test was applied. The variables
independently associated with a poor or very poor quality of life were obtained with a logistic
regression model using the forward selection stepwise method, including variables with significance
under 0.1 in the bivariate analysis.
The comparisons made with the VAS were evaluated using Spearman’s correlation coefficient in
continuous variables and the Mann-Whitney U test in categorical variables. Changes in GCI during
follow-up were assessed using the linear trend chi-square test.
p-Values < 0.05 were considered statistically significant in all comparisons.
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